Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Albireo nets $48.7mm in public stock sale

Executive Summary

Albireo Pharma Inc. (primarily develops liver disease treatments; also has GI projects) netted $48.7mm through a public offering of 2.5mm common shares (including the overallotment) at $20.50. Proceeds are earmarked for Phase III trials of A4250 for progressive familial intrahepatic cholestasis (PFIC); initiation of a trial with A4250 for pediatric cholestatic liver diseases; Phase II study with A3384 for bile acid malabsorption (BAM); and to advance preclinical NASH programs into clinical trials.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies